CLAIMS

1. A method for reducing fucosylation in the monoclonal antibody Itolizumab expressed by a mammalian cell, said method comprising culturing said mammalian cell in a medium containing an elevated concentration of manganese ions in a range of 0.1mM to 0.5mM.

2. The method of claim 1, wherein said mammalian cell is selected from the group consisting of:

    - CHO cells and
    - NSO cells.

3. The method of claim 1, wherein the monoclonal antibody Itolizumab has an afucosylation level of 35% compared to the monoclonal antibody Itolizumab expressed in the absence of said elevated concentration of manganese ions.